vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and PagerDuty, Inc. (PD). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $124.5M, roughly 2.0× PagerDuty, Inc.). PagerDuty, Inc. runs the higher net margin — 129.7% vs 11.1%, a 118.6% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 4.7%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $24.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 5.9%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
PagerDuty, Inc. is an American cloud computing company specializing in a SaaS incident management platform for IT operations departments.
ANIP vs PD — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $124.5M |
| Net Profit | $27.5M | $161.6M |
| Gross Margin | — | 85.3% |
| Operating Margin | 14.1% | 6.5% |
| Net Margin | 11.1% | 129.7% |
| Revenue YoY | 29.6% | 4.7% |
| Net Profit YoY | 367.5% | 2827.7% |
| EPS (diluted) | $1.14 | $1.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $124.5M | ||
| Q3 25 | $227.8M | $123.4M | ||
| Q2 25 | $211.4M | $119.8M | ||
| Q1 25 | $197.1M | $121.4M | ||
| Q4 24 | $190.6M | $118.9M | ||
| Q3 24 | $148.3M | $115.9M | ||
| Q2 24 | $138.0M | $111.2M | ||
| Q1 24 | $137.4M | $111.1M |
| Q4 25 | $27.5M | $161.6M | ||
| Q3 25 | $26.6M | $9.6M | ||
| Q2 25 | $8.5M | $-7.2M | ||
| Q1 25 | $15.7M | $-8.8M | ||
| Q4 24 | $-10.3M | $-5.9M | ||
| Q3 24 | $-24.2M | $-10.9M | ||
| Q2 24 | $-2.3M | $-17.1M | ||
| Q1 24 | $18.2M | $-28.2M |
| Q4 25 | — | 85.3% | ||
| Q3 25 | — | 84.6% | ||
| Q2 25 | — | 84.0% | ||
| Q1 25 | — | 83.6% | ||
| Q4 24 | — | 83.0% | ||
| Q3 24 | — | 82.7% | ||
| Q2 24 | — | 82.6% | ||
| Q1 24 | — | 81.7% |
| Q4 25 | 14.1% | 6.5% | ||
| Q3 25 | 15.9% | 2.9% | ||
| Q2 25 | 6.6% | -8.6% | ||
| Q1 25 | 13.3% | -9.6% | ||
| Q4 24 | -2.3% | -8.7% | ||
| Q3 24 | -13.8% | -13.8% | ||
| Q2 24 | 3.7% | -19.5% | ||
| Q1 24 | 14.8% | -30.1% |
| Q4 25 | 11.1% | 129.7% | ||
| Q3 25 | 11.7% | 7.8% | ||
| Q2 25 | 4.0% | -6.0% | ||
| Q1 25 | 8.0% | -7.2% | ||
| Q4 24 | -5.4% | -5.0% | ||
| Q3 24 | -16.3% | -9.4% | ||
| Q2 24 | -1.7% | -15.4% | ||
| Q1 24 | 13.2% | -25.3% |
| Q4 25 | $1.14 | $1.69 | ||
| Q3 25 | $1.13 | $0.10 | ||
| Q2 25 | $0.36 | $-0.07 | ||
| Q1 25 | $0.69 | $-0.12 | ||
| Q4 24 | $-0.45 | $-0.07 | ||
| Q3 24 | $-1.27 | $-0.14 | ||
| Q2 24 | $-0.14 | $-0.26 | ||
| Q1 24 | $0.82 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $547.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $320.5M |
| Total Assets | $1.4B | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $547.8M | ||
| Q3 25 | $262.6M | $567.9M | ||
| Q2 25 | $217.8M | $597.1M | ||
| Q1 25 | $149.8M | $570.8M | ||
| Q4 24 | $144.9M | $542.2M | ||
| Q3 24 | $145.0M | $599.3M | ||
| Q2 24 | $240.1M | $592.8M | ||
| Q1 24 | $228.6M | $571.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $484.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $489.5M |
| Q4 25 | $540.7M | $320.5M | ||
| Q3 25 | $505.8M | $180.7M | ||
| Q2 25 | $436.8M | $145.7M | ||
| Q1 25 | $418.6M | $129.8M | ||
| Q4 24 | $403.7M | $111.6M | ||
| Q3 24 | $405.9M | $164.7M | ||
| Q2 24 | $455.8M | $174.0M | ||
| Q1 24 | $452.0M | $171.6M |
| Q4 25 | $1.4B | $1.0B | ||
| Q3 25 | $1.4B | $891.5M | ||
| Q2 25 | $1.3B | $926.8M | ||
| Q1 25 | $1.3B | $927.3M | ||
| Q4 24 | $1.3B | $866.8M | ||
| Q3 24 | $1.3B | $916.0M | ||
| Q2 24 | $920.8M | $924.0M | ||
| Q1 24 | $914.5M | $925.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.73× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $24.8M |
| Free Cash FlowOCF − Capex | $29.1M | $24.1M |
| FCF MarginFCF / Revenue | 11.8% | 19.3% |
| Capex IntensityCapex / Revenue | 0.5% | 0.6% |
| Cash ConversionOCF / Net Profit | 1.10× | 0.15× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $117.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $24.8M | ||
| Q3 25 | $44.1M | $34.0M | ||
| Q2 25 | $75.8M | $30.7M | ||
| Q1 25 | $35.0M | $31.4M | ||
| Q4 24 | $15.9M | $22.1M | ||
| Q3 24 | $12.5M | $35.8M | ||
| Q2 24 | $17.4M | $28.6M | ||
| Q1 24 | $18.3M | $22.2M |
| Q4 25 | $29.1M | $24.1M | ||
| Q3 25 | $38.0M | $33.1M | ||
| Q2 25 | $71.8M | $30.2M | ||
| Q1 25 | $32.5M | $30.3M | ||
| Q4 24 | $13.5M | $21.5M | ||
| Q3 24 | $7.7M | $35.1M | ||
| Q2 24 | $13.0M | $28.2M | ||
| Q1 24 | $13.7M | $21.2M |
| Q4 25 | 11.8% | 19.3% | ||
| Q3 25 | 16.7% | 26.8% | ||
| Q2 25 | 34.0% | 25.2% | ||
| Q1 25 | 16.5% | 24.9% | ||
| Q4 24 | 7.1% | 18.1% | ||
| Q3 24 | 5.2% | 30.3% | ||
| Q2 24 | 9.4% | 25.4% | ||
| Q1 24 | 10.0% | 19.1% |
| Q4 25 | 0.5% | 0.6% | ||
| Q3 25 | 2.7% | 0.7% | ||
| Q2 25 | 1.9% | 0.4% | ||
| Q1 25 | 1.3% | 0.9% | ||
| Q4 24 | 1.3% | 0.5% | ||
| Q3 24 | 3.2% | 0.5% | ||
| Q2 24 | 3.2% | 0.4% | ||
| Q1 24 | 3.3% | 0.9% |
| Q4 25 | 1.10× | 0.15× | ||
| Q3 25 | 1.66× | 3.55× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
